Guojuan Dong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Guojuan Dong has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Jialin Jia
Department of Acupuncture and Tuina, Changchun University of Chinese Medicine, Changchun, China
2 shared publicationsTie Li
Department of Acupuncture and Tuina, Changchun University of Chinese Medicine, Changchun, China
2 shared publicationsYan Xu
Henan University of Chinese Medicine
2 shared publications- Anjie Wang
Department of Acupuncture and Tuina, Changchun University of Chinese Medicine, Changchun 130117, China
1 shared publication - Chao Wang
World Federation of Acupuncture-Moxibustion Societies, Beijing, China
1 shared publication Chen Chen
Henan University of Chinese Medicine, Zhengzhou, Henan, China
1 shared publication
Latest Publications
- Open Access
- 17 August 2026
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 26 (1)
Formulating and piloting assessment criteria for filiform needle manipulation techniques in acupuncture education: a sequential e-Delphi and feasibility study
- 17 August 2026
- Published by Springer Nature in BMC Complementary Medicine and Therapies
- Vol. 26 (1)
Open AccessFormulating and piloting assessment criteria for filiform needle manipulation techniques in acupuncture education: a sequential e-Delphi and feasibility study
- Open Access
- 20 April 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1782871
The “two-hit” storm: a hyper-inflammatory endotype in pediatric long COVID and its role in the severity of secondary bacterial pneumonia—a mechanistic review and clinical implications
Following the COVID-19 pandemic, the clinical patterns of pediatric respiratory infections have undergone significant changes, with increasing attention on the immunological imprint left by Post-Acute Sequelae of SARS-CoV-2 infection (PASC), commonly known as Long COVID. A perplexing clinical phenomenon has been observed: some children with a history of Long COVID exhibit a disproportionately severe inflammatory response and extensive lung injury when encountering common community-acquired pneumonia, such as that caused by Mycoplasma pneumoniae or Streptococcus pneumoniae , inconsistent with their pathogen load. This review aims to dissect this phenomenon and proposes the “Immune Priming and Two-Hit” model as its core pathophysiological framework. This model posits that the Long COVID state constitutes the “first hit,” establishing a “primed” or “hyper-reactive” immune baseline through viral persistence, trained immunity-induced monocyte reprogramming, and sustained endothelial dysfunction. Upon the “second hit” of a bacterial infection, this primed immune system triggers a dysregulated, synergistically amplified inflammatory cascade. The mechanisms involve the exponential release of cytokines such as Interleukin-6 (IL-6), IL-1β, and Tumor Necrosis Factor- α (TNF-α), inflammation-mediated immunothrombosis, and excessive activation of Neutrophil Extracellular Trap formation (NETosis), ultimately leading to severe outcomes like Acute Respiratory Distress Syndrome (ARDS) and necrotizing pneumonia. Consequently, identifying and defining this “Hyper-inflammatory endotype” is of critical clinical importance. We define it as an “endotype” to emphasize the distinct, host-determined pathophysiological mechanisms underlying it, rather than merely a collection of clinical manifestations. By monitoring biomarkers such as ferritin, D-dimer, lactate dehydrogenase (LDH), and lymphocyte counts, clinicians may be able to perform early risk stratification of these children. This approach not only facilitates a shift in therapeutic strategy from purely antimicrobial therapy to “host-directed therapy”—emphasizing the necessity of early, adequate corticosteroid use and consideration of anticoagulation—but also provides a new theoretical basis and intervention window for preventing long-term sequelae such as pulmonary fibrosis.
- 20 April 2026
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 14, 1782871
Open AccessThe “two-hit” storm: a hyper-inflammatory endotype in pediatric long COVID and its role in the severity of secondary bacterial pneumonia—a mechanistic review and clinical implications
Following the COVID-19 pandemic, the clinical patterns of pediatric respiratory infections have undergone significant changes, with increasing attention on the immunological imprint left by Post-Acute Sequelae of SARS-CoV-2 infection (PASC), commonly known as Long COVID. A perplexing clinical phenomenon has been observed: some children with a history of Long COVID exhibit a disproportionately severe inflammatory response and extensive lung injury when encountering common community-acquired pneumonia, such as that caused by Mycoplasma pneumoniae or Streptococcus pneumoniae , inconsistent with their pathogen load. This review aims to dissect this phenomenon and proposes the “Immune Priming and Two-Hit” model as its core pathophysiological framework. This model posits that the Long COVID state constitutes the “first hit,” establishing a “primed” or “hyper-reactive” immune baseline through viral persistence, trained immunity-induced monocyte reprogramming, and sustained endothelial dysfunction. Upon the “second hit” of a bacterial infection, this primed immune system triggers a dysregulated, synergistically amplified inflammatory cascade. The mechanisms involve the exponential release of cytokines such as Interleukin-6 (IL-6), IL-1β, and Tumor Necrosis Factor- α (TNF-α), inflammation-mediated immunothrombosis, and excessive activation of Neutrophil Extracellular Trap formation (NETosis), ultimately leading to severe outcomes like Acute Respiratory Distress Syndrome (ARDS) and necrotizing pneumonia. Consequently, identifying and defining this “Hyper-inflammatory endotype” is of critical clinical importance. We define it as an “endotype” to emphasize the distinct, host-determined pathophysiological mechanisms underlying it, rather than merely a collection of clinical manifestations. By monitoring biomarkers such as ferritin, D-dimer, lactate dehydrogenase (LDH), and lymphocyte counts, clinicians may be able to perform early risk stratification of these children. This approach not only facilitates a shift in therapeutic strategy from purely antimicrobial therapy to “host-directed therapy”—emphasizing the necessity of early, adequate corticosteroid use and consideration of anticoagulation—but also provides a new theoretical basis and intervention window for preventing long-term sequelae such as pulmonary fibrosis.
- Open Access
- 10 March 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1728742
From data mining to experimental validation: ST36 and CV12 as core acupoint combination for acupuncture in functional dyspepsia
Background: Effective treatments for functional dyspepsia (FD) remain elusive. Acupuncture presents promising potential due to its safety and minimal side effects. However, variability in acupoint prescriptions in clinical practice has hindered the optimization and dissemination of treatment protocols for FD. This study seeks to screen out the core acupoint combination, and experimentally validate its efficacy. Methods: This study involved searching eight databases to analyze acupoint prescriptions in the literature using data mining and association rules. The aim was to identify an acupoint combination based on prescription frequency, co-occurrence patterns, and network relevance as a core prescription. Subsequently, we established the FD rat model. The rats were randomly assigned to control, model, electroacupuncture, and Itopride groups ( n = 6 per group). All interventions lasted 14 days. The body weight, 3 h food intake, and gastric emptying rate were assessed in each group. Eosinophil (Eos) and mast cell (MC) counts in duodenal tissues were determined using Eos staining and toluidine blue staining, respectively. Pathological changes in duodenal tissues were examined through hematoxylin–eosin (H&E) staining, while immunofluorescence (IF) staining was employed to evaluate the expression levels of tight junction proteins Claudin-1 and Occludin in the duodenal mucosal barrier. Results: The data mining results revealed ST36 as the most frequently utilized acupoint, with its combination with CV12 being the most prevalent. Network association analysis showed the interconnections among them. Integrating multiple analytical methods, this study ultimately suggests the central role of ST36 and CV12 in acupoint prescriptions for the treatment of FD. Animal experiments demonstrated that electroacupuncture stimulation of these two acupoints significantly improved digestive function and nutritional status in FD rats. Eos staining and toluidine blue staining indicated a marked reduction in Eos and MC infiltration. Histological examination showed restoration of duodenal villi structure, while IF further showed increased expression of Claudin-1 and Occludin. Conclusion: This study showed that ST36 and CV12 are the core acupoint combination of acupuncture for FD. Animal experiments further demonstrated that electroacupuncture stimulation of these two acupoints could significantly alleviate the duodenal low-grade inflammation and mucosal barrier damage in FD rats.
- 10 March 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1728742
Open AccessFrom data mining to experimental validation: ST36 and CV12 as core acupoint combination for acupuncture in functional dyspepsia
Background: Effective treatments for functional dyspepsia (FD) remain elusive. Acupuncture presents promising potential due to its safety and minimal side effects. However, variability in acupoint prescriptions in clinical practice has hindered the optimization and dissemination of treatment protocols for FD. This study seeks to screen out the core acupoint combination, and experimentally validate its efficacy. Methods: This study involved searching eight databases to analyze acupoint prescriptions in the literature using data mining and association rules. The aim was to identify an acupoint combination based on prescription frequency, co-occurrence patterns, and network relevance as a core prescription. Subsequently, we established the FD rat model. The rats were randomly assigned to control, model, electroacupuncture, and Itopride groups ( n = 6 per group). All interventions lasted 14 days. The body weight, 3 h food intake, and gastric emptying rate were assessed in each group. Eosinophil (Eos) and mast cell (MC) counts in duodenal tissues were determined using Eos staining and toluidine blue staining, respectively. Pathological changes in duodenal tissues were examined through hematoxylin–eosin (H&E) staining, while immunofluorescence (IF) staining was employed to evaluate the expression levels of tight junction proteins Claudin-1 and Occludin in the duodenal mucosal barrier. Results: The data mining results revealed ST36 as the most frequently utilized acupoint, with its combination with CV12 being the most prevalent. Network association analysis showed the interconnections among them. Integrating multiple analytical methods, this study ultimately suggests the central role of ST36 and CV12 in acupoint prescriptions for the treatment of FD. Animal experiments demonstrated that electroacupuncture stimulation of these two acupoints significantly improved digestive function and nutritional status in FD rats. Eos staining and toluidine blue staining indicated a marked reduction in Eos and MC infiltration. Histological examination showed restoration of duodenal villi structure, while IF further showed increased expression of Claudin-1 and Occludin. Conclusion: This study showed that ST36 and CV12 are the core acupoint combination of acupuncture for FD. Animal experiments further demonstrated that electroacupuncture stimulation of these two acupoints could significantly alleviate the duodenal low-grade inflammation and mucosal barrier damage in FD rats.
- Open Access
Research Progress on the Efficacy and Mechanism of Acupuncture in Treating Chronic Gastritis
Chronic gastritis (CG) is a prevalent digestive disorder. It progresses through multiple stages, has an insidious onset, and can lead to severe complications if untreated. Modern treatments primarily aim to eradicate Helicobacter pylori and relieve symptoms. However, drug resistance and adverse effects often limit their effectiveness. As a primary traditional Chinese medicine (TCM) therapy, acupuncture treats CG through multi-target mechanisms. This review systematically outlines the classification and pathology of CG. It also comprehensively analyzes animal and clinical studies on acupuncture for CG from the past decade. The study summarizes the mechanisms of acupuncture and related therapies for CG, covering gastric mucosal function, metabolism, intestinal flora, gastrointestinal hormones, apoptosis, inflammation, and oxidative stress. It further explores the relationships among diseases, interventions, acupoints, and molecular pathways. Additionally, it compares the therapeutic profiles of different external therapies. The review also examines the current state of clinical research, including the selection of acupoints, treatment duration, and outcome assessment. The results demonstrate that external therapies effectively alleviate common CG symptoms such as abdominal distension, acid reflux, and stomach pain. These treatments also improve gastric mucosal health and modulate serum levels of inflammatory factors, oxidative stress markers, and gastrointestinal hormones. In vivo experiments using chronic non-atrophic gastritis (CNAG) and chronic atrophic gastritis (CAG) models confirm these benefits, showing changes in key biomarkers and elucidating potential mechanisms. Nevertheless, future high-quality, large-sample clinical trials are still needed to firmly establish efficacy. Further mechanistic studies are also needed to validate the interconnections among relevant signaling pathways.
Open AccessResearch Progress on the Efficacy and Mechanism of Acupuncture in Treating Chronic Gastritis
Chronic gastritis (CG) is a prevalent digestive disorder. It progresses through multiple stages, has an insidious onset, and can lead to severe complications if untreated. Modern treatments primarily aim to eradicate Helicobacter pylori and relieve symptoms. However, drug resistance and adverse effects often limit their effectiveness. As a primary traditional Chinese medicine (TCM) therapy, acupuncture treats CG through multi-target mechanisms. This review systematically outlines the classification and pathology of CG. It also comprehensively analyzes animal and clinical studies on acupuncture for CG from the past decade. The study summarizes the mechanisms of acupuncture and related therapies for CG, covering gastric mucosal function, metabolism, intestinal flora, gastrointestinal hormones, apoptosis, inflammation, and oxidative stress. It further explores the relationships among diseases, interventions, acupoints, and molecular pathways. Additionally, it compares the therapeutic profiles of different external therapies. The review also examines the current state of clinical research, including the selection of acupoints, treatment duration, and outcome assessment. The results demonstrate that external therapies effectively alleviate common CG symptoms such as abdominal distension, acid reflux, and stomach pain. These treatments also improve gastric mucosal health and modulate serum levels of inflammatory factors, oxidative stress markers, and gastrointestinal hormones. In vivo experiments using chronic non-atrophic gastritis (CNAG) and chronic atrophic gastritis (CAG) models confirm these benefits, showing changes in key biomarkers and elucidating potential mechanisms. Nevertheless, future high-quality, large-sample clinical trials are still needed to firmly establish efficacy. Further mechanistic studies are also needed to validate the interconnections among relevant signaling pathways.
- Open Access
- 2 October 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1664776
Clinical characteristics, molecular mechanisms, and exploration of association with gastrointestinal symptoms in CHAMP1 gene variation-related neurodevelopmental disorders
The CHAMP1 (Chromosome Alignment-Maintaining Phosphoprotein 1) gene encodes a nuclear protein crucial for maintaining proper chromosome alignment and genomic stability during cell mitosis. Heterozygous variants of this gene, particularly de novo truncating mutations, are the primary cause of a rare neurodevelopmental disorder: autosomal dominant intellectual disability Autosomal Dominant Mental Retardation 40 (MRD40) or CHAMP1-related Neurodevelopmental Disorder (CHAND). The core clinical features of this disorder include moderate to severe global developmental delay, intellectual disability, significant language impairment, and distinctive facial features. Additionally, patients may exhibit abnormal muscle tone, behavioral issues (such as autism spectrum disorder traits and attention deficit hyperactivity disorder), epilepsy, microcephaly, and involvement of other multi-systemic complications, including gastrointestinal dysfunction. The pathogenic mechanisms of CHAMP1 truncating mutations remain debated, with main hypotheses including haploinsufficiency and dominant-negative effect or gain-of-function, where the latter better explains the more severe clinical phenotypes observed in some patients. Although neurological manifestations are the research focus of CHAMP1-related disorders, the involvement of other systems such as the digestive system—particularly symptoms like repeated vomiting—has been underreported and lacks systematic research within this disease spectrum. This review aims to integrate the latest research progress on the molecular functions of the CHAMP1 gene, the pathogenic mechanisms of its variants, and the clinical phenotype spectrum of related neurodevelopmental disorders. Based on clinical observations, we also preliminarily explored the potential association between CHAMP1 gene variation and gastrointestinal symptoms (especially recurrent vomiting), with the goal of providing valuable references for clinical diagnosis, management, and future research directions for this rare disease.
- 2 October 2025
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1664776
Open AccessClinical characteristics, molecular mechanisms, and exploration of association with gastrointestinal symptoms in CHAMP1 gene variation-related neurodevelopmental disorders
The CHAMP1 (Chromosome Alignment-Maintaining Phosphoprotein 1) gene encodes a nuclear protein crucial for maintaining proper chromosome alignment and genomic stability during cell mitosis. Heterozygous variants of this gene, particularly de novo truncating mutations, are the primary cause of a rare neurodevelopmental disorder: autosomal dominant intellectual disability Autosomal Dominant Mental Retardation 40 (MRD40) or CHAMP1-related Neurodevelopmental Disorder (CHAND). The core clinical features of this disorder include moderate to severe global developmental delay, intellectual disability, significant language impairment, and distinctive facial features. Additionally, patients may exhibit abnormal muscle tone, behavioral issues (such as autism spectrum disorder traits and attention deficit hyperactivity disorder), epilepsy, microcephaly, and involvement of other multi-systemic complications, including gastrointestinal dysfunction. The pathogenic mechanisms of CHAMP1 truncating mutations remain debated, with main hypotheses including haploinsufficiency and dominant-negative effect or gain-of-function, where the latter better explains the more severe clinical phenotypes observed in some patients. Although neurological manifestations are the research focus of CHAMP1-related disorders, the involvement of other systems such as the digestive system—particularly symptoms like repeated vomiting—has been underreported and lacks systematic research within this disease spectrum. This review aims to integrate the latest research progress on the molecular functions of the CHAMP1 gene, the pathogenic mechanisms of its variants, and the clinical phenotype spectrum of related neurodevelopmental disorders. Based on clinical observations, we also preliminarily explored the potential association between CHAMP1 gene variation and gastrointestinal symptoms (especially recurrent vomiting), with the goal of providing valuable references for clinical diagnosis, management, and future research directions for this rare disease.